A trial looking at different doses of Herceptin with chemotherapy for advanced HER2 positive cancer of the stomach or cancer where the stomach meets the oesophagus (gastro oesophageal junction cancer)

This trial is looking at different doses of trastuzumab (Herceptin) alongside chemotherapy for stomach cancer, or cancer where the food pipe (oesophagus) meets the stomach (gastro oesophageal junction cancer). The people taking part have cancer that has spread to at least 2 other places in the body and has large amounts of a protein called HER2.

Doctors can use a biological therapy drug called Herceptin with chemotherapy for stomach cancer or gastro oesophageal cancer that has spread to other parts of the body. It only works for people whose cancer cells have large amounts of a protein called human epidermal growth factor receptor 2 (HER2). This is known as HER2 positive cancer.

In this trial, researchers want to see if having a higher dose of Herceptin alongside chemotherapy will help people more than the standard dose that is currently used.

The aims of the trial are to find out

• How different doses of Herceptin affect people with HER2 positive cancer of the stomach or gastro oesophageal junction

• See if a higher dose of Herceptin stays in the blood for longer and helps people more than the standard dose